104 related articles for article (PubMed ID: 26648164)
41. Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells.
Lien JC; Hung CM; Lin YJ; Lin HC; Ko TC; Tseng LC; Kuo SC; Ho CT; Lee JC; Way TD
Chem Biol Interact; 2015 Jun; 235():17-26. PubMed ID: 25866362
[TBL] [Abstract][Full Text] [Related]
42. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
43. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
44. RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Sep; 41(3):1119-27. PubMed ID: 22710975
[TBL] [Abstract][Full Text] [Related]
45. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Wu CW; Lui WY
Eur J Clin Invest; 2006 Aug; 36(8):588-96. PubMed ID: 16893382
[TBL] [Abstract][Full Text] [Related]
46. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Choi YH; Yoo YH
Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
48. [Effects of single versus combined use of trastuzumab and cantide on breast cancer cells SKBR3 over-expressing HER2].
Zhang F; Yang JL; You JH; Feng F; Ren L; Xie WX; Li ZJ
Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1384-7. PubMed ID: 22883194
[TBL] [Abstract][Full Text] [Related]
49. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models.
Chakraborty AK; Mehra R; Digiovanna MP
Anticancer Res; 2015 Mar; 35(3):1243-50. PubMed ID: 25750271
[TBL] [Abstract][Full Text] [Related]
50. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
51. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.
Shen Y; Du Y; Zhang Y; Pan Y
Mol Med Rep; 2015 Jul; 12(1):456-62. PubMed ID: 25738757
[TBL] [Abstract][Full Text] [Related]
52. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
[TBL] [Abstract][Full Text] [Related]
53. Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Kasukabe T; Okabe-Kado J; Kato N; Honma Y; Kumakura S
Int J Oncol; 2015 Feb; 46(2):841-8. PubMed ID: 25405645
[TBL] [Abstract][Full Text] [Related]
54. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR; Hosford SR; Symonds LK; Owens P; Dillon LM; Yang W; Shee K; Schwartz GN; Marotti JD; Muller KE; Rosenkranz KM; Barth RJ; Chen VS; Agarwal VR; Miller TW
Breast Cancer Res Treat; 2015 Jan; 149(1):69-79. PubMed ID: 25491778
[TBL] [Abstract][Full Text] [Related]
55. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
[TBL] [Abstract][Full Text] [Related]
56. Piperlongumine downregulates the expression of HER family in breast cancer cells.
Jin HO; Park JA; Kim HA; Chang YH; Hong YJ; Park IC; Lee JK
Biochem Biophys Res Commun; 2017 May; 486(4):1083-1089. PubMed ID: 28377224
[TBL] [Abstract][Full Text] [Related]
57. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells.
Xiao H; Claret FX; Shen Q
Neoplasma; 2019 May; 66(3):481-486. PubMed ID: 30868895
[TBL] [Abstract][Full Text] [Related]
58. Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells.
Pierpaoli E; Fiorillo G; Lombardi P; Salvatore C; Geroni C; Piacenza F; Provinciali M
Biofactors; 2018 Sep; 44(5):443-452. PubMed ID: 30178609
[TBL] [Abstract][Full Text] [Related]
59. Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies.
Keegan BP; Akerman BL; Péqueux C; North WG
Breast Cancer Res Treat; 2006 Feb; 95(3):265-77. PubMed ID: 16331351
[TBL] [Abstract][Full Text] [Related]
60. IR-783 inhibits breast cancer cell proliferation and migration by inducing mitochondrial fission.
Li P; Liu Y; Liu W; Li G; Tang Q; Zhang Q; Leng F; Sheng F; Hu C; Lai W; Liu Y; Zhou M; Huang J; Zhou H; Zhang R; Zhao Y
Int J Oncol; 2019 Aug; 55(2):415-424. PubMed ID: 31173174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
